
Top Ten articles in the pharma industry this week
pharmafile | November 4, 2016 | News story | Medical Communications |Â Â November, news, pharmaceutical, top 10, top ten, top ten storiesÂ
This week has seen pharmaceutical companies release their third quarter profits, good news for some whilst others have attempted to use the release of the news to hide some not-so-positive news. Read here to catch up on this and the other biggest news stories that have been viewed on our website.
10. Hard times continue for Valeant as ex-CEO investigated for fraud
Valeant Pharmaceuticals former CEO, J. Michael Pearson, and CFO, Howard Schiller, could potentially face criminal charges over the company’s actions with Philidor Rx Services regarding accounting revenues.
9. FDA issues warning letter after Chinese firm impedes investigation
The FDA has issued a Chinese firm with a warning letter after claims it intentionally impeded an inspection of its facility in November 2015.
8. MSD’s Alzheimer’s study could break new ground for treatment
MSD, known as Merck in North America, have released encouraging results from a Phase I trial for a drug potentially slowing the mental decline associated with Alzheimer’s disease.
7. Teva sets out to delay generic competitor to Copaxone
Teva submits documents to the FDA regarding the difference in composition between Copaxone 40mg and its generic competitors.
6. NICE approves first new drug for breast cancer in a decade
NICE has approved Halaven for routine treatment, four years after it was rejected. It becomes the first new drug for treatment of metastatic breast cancer for a decade.
5. AstraZeneca’s head and neck cancer treatment clinical trials put on hold
AstraZeneca’s drug is placed on a partial hold in clinical trials due to the increased incidence in bleeding for those patients involved in the trial.
4. FDA rejects Sarilumab due to production facility issues
Regeneron and Sanofi’s rheumatoid arthritis treatment rejected on the basis of issues identified at a Sanofi facility where the drug’s production is finished.
3. Lily increases diabetes drug by 700% over 20 years
A tweet from Vermont Senator Bernie Sanders’ account brought the increase to public attention and sent shares crashing.
2. Gilead quietly drops drugs from line up alongide Q3 results
Gilead Sciences followed Pfizer in discreetly dropping a drug alongside its third quarter profit reports.
1. Pfizer surprises industry by ending development of projected blockbuster
Pfizer announced, alonside Q3 profit reports, the news that it would no longer be developing an experimental cholesterol lowering drug.
Related Content

ProBioGen secures extended GMP authorisation for viral manufacturing facility
ProBioGen has secured extended manufacturing authorisation and an updated Good Manufacturing Practice (GMP) certificate for …

Digital platform cuts pharmaceutical quality-record approval times by up to 90%
A digital platform for exchanging pharmaceutical quality records between supply-chain partners is now commercially available, …

Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster
By Chris Moore Commercial engagement in biopharma used to centre largely on direct conversations between …






